Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ethambutol
Drug ID BADD_D00841
Description Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis.[L31743] Ethambutol was first described in the literature in 1961.[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.[A229048] Ethambutol was granted FDA approval on 6 November 1967.[L31663]
Indications and Usage For use, as an adjunct, in the treatment of pulmonary tuberculosis.
Marketing Status Prescription; Discontinued
ATC Code J04AK02
DrugBank ID DB00330
KEGG ID D07925
MeSH ID D004977
PubChem ID 14052
TTD Drug ID D08QME
NDC Product Code 60592-243
Synonyms Ethambutol | Dexambutol | Etibi | EMB-Fatol | EMB Fatol | Etambutol Llorente | Llorente, Etambutol | Ethambutol Hydrochloride | Hydrochloride, Ethambutol | Myambutol | Miambutol | EMB-Hefa | EMB Hefa
Chemical Information
Molecular Formula C10H24N2O2
CAS Registry Number 74-55-5
SMILES CCC(CO)NCCNC(CC)CO
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.004591%Not Available
Abdominal pain07.01.05.002--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Arthralgia15.01.02.001--
Asthenia08.01.01.0010.004591%Not Available
Blindness17.17.01.003; 06.02.02.001--Not Available
Blood thyroid stimulating hormone increased13.10.03.0060.004591%
Body temperature increased13.15.01.001--Not Available
Cardio-respiratory arrest02.03.04.002; 22.02.06.0070.001198%Not Available
Coagulopathy01.01.02.0010.004591%Not Available
Colour blindness03.01.01.001; 06.02.09.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Dermatitis23.03.04.002--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Discomfort08.01.08.003--Not Available
Disorientation17.02.05.015; 19.13.01.002--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dysaesthesia17.02.06.0030.004591%
Dysgeusia17.02.07.003; 07.14.03.0010.004591%
Dyspnoea22.02.01.004; 02.01.03.0020.006887%
Eosinophilia01.02.04.001--
Erythema multiforme23.03.01.003; 10.01.03.015--
Feeling abnormal08.01.09.014--Not Available
Gastrointestinal pain07.01.05.005--
Generalised oedema14.05.06.007; 08.01.07.0040.004591%
Gout15.01.06.001; 14.09.01.001--Not Available
Hallucination19.10.02.002--
Headache17.14.01.001--
Hepatic function abnormal09.01.02.001--Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages